NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a clinical-stage biopharmaceutical company, announced today that Christine Sindt OD, Clinical Associate Professor of Ophthalmology and Visual Sciences at University of Iowa’s Carver College of Medicine, will describe the benefits of treating common eye and eyelid conditions using NovaBay’s new i-LidTM Cleanser on June 27, 2014 during the annual Optometry’s Meeting® of the American Optometric Association in Philadelphia, PA. NovaBay representatives will be available at the AOA Meeting in Booth #1615 to meet with eye care professionals interested in learning more about i-Lid Cleanser and placing orders for product to be shipped to their practice.
“Based on my own experience using i-Lid Cleanser, I believe that it offers significant improvements in the treatment of common eyelid conditions,” said Dr. Sindt.
Dr. Sindt founded the Scleral Lens Education Society and is a nationally recognized expert on specialty contact lenses for children. Her practice specializes in the treatment of anterior segment disease and has had extensive clinical experience with i-Lid Cleanser.
For example, an estimated 23 million Americans suffer from moderate to severe blepharitis. Often triggered by Staph bacteria growing on eyelids, blepharitis leads to swelling, redness, inflammation, irritation and a crusty build-up on the eyelids.
As Dr. Sindt will explain, optometrists and ophthalmologists have typically treated blepharitis with antibiotics and steroids. But that approach doesn’t work very well, and it also raises concerns over antibiotic resistance and side effects. In contrast, i-Lid Cleanser contains a pure, stable form of hypochlorous acid, a substance naturally made by the body’s immune system as a first defense against microbial invaders. Lab tests show that it kills bacteria, neutralizes the toxins produced by bacteria, and clinical experience has shown it effectively removes debris from the eyelids—and is completely safe.
Dr. Sindt will describe how, in her own practice, i-Lid Cleanser has been effective against blepharitis and other conditions, such as rosacea of the eyelids. “My patients report that they are getting relief from these often-painful eyelid conditions,” said Dr. Sindt.
The full meeting will be held at the Pennsylvania Convention Center from June 25-29, 2014. “The successes that leading eye doctors like Dr. Sindt have had with i-Lid Cleanser show that our product can make a real difference in patients’ lives,” said Dr. Ron Najafi, CEO of NovaBay. “We are grateful to Dr. Sindt for sharing her expertise and experiences with her fellow optometrists.”
This release contains forward-looking statements and opinions, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs, and also those of unaffiliated individuals. These statements include, but are not limited to, statements regarding the general effectiveness of NovaBay’s products and the quoted opinions of certain physicians. The words “believe,” “estimated,” “show,” and “can” are intended to identify these forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the actual effectiveness of NovaBay products and unexpected adverse side effects or inadequate therapeutic efficacy of i-Lid Cleanser. Other risks relating to NovaBay and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay’s progress:
Download our Mobile InvestorApp from the Apple Store or Google Play
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website
NovaBay Pharmaceuticals Contacts
Thomas J. Paulson
Chief Financial Officer
Contact Thomas Paulson